An Open-label Study to Investigate the Safety, Tolerability and Efficacy of a Single 6-hour Intravenous Infusion of AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2020
Price : $35 *
At a glance
- Drugs Diazepinomicin (Primary)
- Indications Telomeric 22q13 Monosomy Syndrome
- Focus Adverse reactions
- 17 Jun 2019 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.
- 17 Jun 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2020.
- 23 Apr 2019 Planned End Date changed from 31 Mar 2019 to 1 Jul 2019.